Novartis Investigative Site

Utrecht, Netherlands 3584CX

0 studies enrolling now · 5 studies all time

What they study most

Dumping Syndrome, Locally Advanced Metastatic BRAF Mutant Melanoma, Lymphangioleiomyomatosis (LAM), Metastatic Renal Cell Carcinoma, Subependymal Giant Cell Astrocytoma, Tuberous Sclerosis, Tuberous Sclerosis Complex (TSC)

Studies at this site

• Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome — Completed
• Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) — Completed
• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. — Stopped early
• Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed